Friday 6 November 2026 Export ZYME’s income statement to Excel — free account

Zymeworks Inc.

ZYME Healthcare Biotechnology

Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.

Revenue: −90.6%
EPS: −2,166.7%
Free cash flow: −385.5%

Quarter to June 2026, against a year earlier

29.52 0.78 +2.71%

Follow ZYME

Alert me

Market cap: $2.0B
P/E: 0.0×
Fwd P/E: 26.0×
Dividend yield: —
F-score: 7/9
Altman Z: 11.56
Beneish M: n/a
Dividend safety: n/a

Overview

Zymeworks Inc. (ZYME) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Zymeworks Inc. (ZYME) trades at a P/B ratio of 26.2×. Over the past ten years it has ranged from 0.0× (June 2017) to 28.2× (September 2026); the current reading is higher than 100% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ZYME/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Zymeworks Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ZYME/metrics/pb-ratio">Zymeworks Inc. (ZYME) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	7.4×	125.59%
FY2024	3.3×	113.15%
FY2023	1.5×	54.21%
FY2022	1.0×	(70.60%)
FY2021	3.4×	(41.60%)
FY2020	5.8×	(17.44%)
FY2019	7.0×	197.36%
FY2018	2.4×	63.48%
FY2017	1.4×	—
FY2016	0.0×	—

Period	P/B ratio	Change
Jun 2026	23.7×	107.72%
Mar 2026	11.4×	54.57%
Dec 2025	7.4×	82.88%
Sep 2025	4.0×	43.05%
38 more quarters	Free account

Against its own ten years

Low 0.0× High 28.2×

Ten-year median 2.8×

Current reading's percentile 100

Company	P/B ratio
BHVN Biohaven Ltd. compare	n/m
LKFT Lakefront Biotherapeutics - Sponsored ADR compare	0.6×
COAG Hemab Therapeutics Holdings, Inc. compare	3.0×
AUPH Aurinia Pharmaceuticals Inc compare	3.3×
IMNM Immunome, Inc. compare	3.9×
VERA Vera Therapeutics, Inc. compare	5.3×
SEPN Septerna, Inc. compare	5.6×
VCEL Vericel Corporation compare	6.8×
ZYME Zymeworks Inc.	26.2×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Zymeworks Inc. (ZYME) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on ZYME

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on ZYME

Stockrow Weekly